Who founded HistoWiz?

HistoWiz was founded by Ke Cheng in 2012.

Who are HistoWiz's investors?

HistoWiz's investors include Asahi Kasei Corporate Venture Capital, venBio Partners, Vivo Capital, Y Combinator, Avlok Capital, K5 Ventures, MicroVentures.

How much funding has HistoWiz raised?

HistoWiz has disclosed $1.3M raised across 2 of its 3 known rounds.

Where is HistoWiz headquartered?

HistoWiz is headquartered in New York City, US.

HistoWiz

YC W16

New York City, US · Founded 2012 · New York corporation · 2 employees · 9 known investors

Find your way into HistoWiz

Paths you didn't know you had: your email and LinkedIn already hold routes to the HistoWiz team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories. The company serves biomedical researchers, pharmaceutical companies, and diagnostic labs with automated histology processing and pathology consultation.

AI & Machine Learning Biotech Healthtech Medical Devices AIUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W16)

HistoWiz was founded in 2012 by Ke Cheng.

Ke ChengCEOformer

Linh HoangChief Executive Officer

Jerry KuangChief Operations Officer

Julie Feldstein Chief PathologistDr. Julie Teruya-Feldstein directed hematopathology and immunohistochemistry at Memorial Sloan Kettering Cancer Center for over 15 years and was a professor of hematopathology at the Icahn School of Medicine at Mount Sinai; she has authored over 200 peer-reviewed publications and serves as Chief Pathologist at HistoWiz, overseeing its telepathology services.

Investors · 9

Asahi Kasei Corporate Venture Capitallisted by Asahi Kasei Corporate Venture CapitalMenlo Park · $200K – $5M

How we know: Asahi Kasei Corporate Venture Capital's portfolio page · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · funding news · drug-dev.com · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Avlok CapitalreportedLynnwood

How we know: Y Combinator's founder network · Not right? Tell us

K5 VenturesreportedIrvine · $25K

How we know: Y Combinator's founder network · Not right? Tell us

MicroVenturesreportedAustin

How we know: Y Combinator's founder network · Not right? Tell us

Also in the syndicate · 2

Asahi KaseivenBio

Funding

SEC filings, press & company announcements

$1.3M disclosed across 2 of 3 rounds · 2015–2021

Undisclosed amountSeries AOct 2021 · 2 sources
Vivo Capital (lead), Asahi Kasei, venBio
Source ↗

▶$344.5KraisedJun 2016 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ke ChengExecutive Officer, Director

Offering amount: $350K
Amount sold: $344.5K
First sale: Mar 2016
Incorporated: Corporation, New York, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedMar 2015 · 1 investors · Biotechnology

Officers, directors & promoters on the filing

Ke ChengExecutive Officer, Director

Offering amount: $1M
Amount sold: $1M
Minimum investment: $1M
Proceeds to insiders: $40K
First sale: Feb 2015
Incorporated: Corporation, New York, 2012
Federal exemptions: 04

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

The YC application· Winter 2016 batch

YC Demo Day W16-HistoWiz

Ke Cheng

Related companies · 8

Yemaachi BiotechnologyYemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.

IsablIsabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.

ResistanceBioResistanceBio develops treatments to address drug resistance in cancer patients.

AbcamSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.

zPREDICTAzPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.

Algen BiotechnologiesAlgen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

AgilentAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).

Companies working in the same space as HistoWiz.

Legal entities · 1

corporate structure

Histowiz, Inc.

In the news

HistoWiz Raises $32 Million in Series Athesaasnews.com · Oct 2021

Frequently asked questions

What does HistoWiz do?: HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories. The company serves biomedical researchers, pharmaceutical companies, and diagnostic labs with automated histology processing and pathology consultation.
Who founded HistoWiz?: HistoWiz was founded by Ke Cheng in 2012.
Who are HistoWiz's investors?: HistoWiz's investors include Asahi Kasei Corporate Venture Capital, venBio Partners, Vivo Capital, Y Combinator, Avlok Capital, K5 Ventures, MicroVentures.
How much funding has HistoWiz raised?: HistoWiz has disclosed $1.3M raised across 2 of its 3 known rounds.
Where is HistoWiz headquartered?: HistoWiz is headquartered in New York City, US.